275 related articles for article (PubMed ID: 15477345)
1. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions.
Lodoen MB; Abenes G; Umamoto S; Houchins JP; Liu F; Lanier LL
J Exp Med; 2004 Oct; 200(8):1075-81. PubMed ID: 15477345
[TBL] [Abstract][Full Text] [Related]
2. Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein.
Hasan M; Krmpotic A; Ruzsics Z; Bubic I; Lenac T; Halenius A; Loewendorf A; Messerle M; Hengel H; Jonjic S; Koszinowski UH
J Virol; 2005 Mar; 79(5):2920-30. PubMed ID: 15709011
[TBL] [Abstract][Full Text] [Related]
3. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules.
Lodoen M; Ogasawara K; Hamerman JA; Arase H; Houchins JP; Mocarski ES; Lanier LL
J Exp Med; 2003 May; 197(10):1245-53. PubMed ID: 12756263
[TBL] [Abstract][Full Text] [Related]
4. Promiscuity of MCMV immunoevasin of NKG2D: m138/fcr-1 down-modulates RAE-1epsilon in addition to MULT-1 and H60.
Arapović J; Lenac Rovis T; Reddy AB; Krmpotić A; Jonjić S
Mol Immunol; 2009 Nov; 47(1):114-22. PubMed ID: 19297023
[TBL] [Abstract][Full Text] [Related]
5. The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60.
Lenac T; Budt M; Arapovic J; Hasan M; Zimmermann A; Simic H; Krmpotic A; Messerle M; Ruzsics Z; Koszinowski UH; Hengel H; Jonjic S
J Exp Med; 2006 Aug; 203(8):1843-50. PubMed ID: 16831899
[TBL] [Abstract][Full Text] [Related]
6. NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145.
Krmpotic A; Hasan M; Loewendorf A; Saulig T; Halenius A; Lenac T; Polic B; Bubic I; Kriegeskorte A; Pernjak-Pugel E; Messerle M; Hengel H; Busch DH; Koszinowski UH; Jonjic S
J Exp Med; 2005 Jan; 201(2):211-20. PubMed ID: 15642742
[TBL] [Abstract][Full Text] [Related]
7. Differential susceptibility of RAE-1 isoforms to mouse cytomegalovirus.
Arapovic J; Lenac T; Antulov R; Polic B; Ruzsics Z; Carayannopoulos LN; Koszinowski UH; Krmpotic A; Jonjic S
J Virol; 2009 Aug; 83(16):8198-207. PubMed ID: 19494006
[TBL] [Abstract][Full Text] [Related]
8. Murine CMV Expressing the High Affinity NKG2D Ligand MULT-1: A Model for the Development of Cytomegalovirus-Based Vaccines.
Hiršl L; Brizić I; Jenuš T; Juranić Lisnić V; Reichel JJ; Jurković S; Krmpotić A; Jonjić S
Front Immunol; 2018; 9():991. PubMed ID: 29867968
[TBL] [Abstract][Full Text] [Related]
9. [Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response].
Li XF; Chen Q; Ye YB; Fan LF; Chen MS; Li JY; Chen HQ; Chen SP; Zhou ZF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):160-4. PubMed ID: 17490545
[TBL] [Abstract][Full Text] [Related]
10. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
Bui JD; Carayannopoulos LN; Lanier LL; Yokoyama WM; Schreiber RD
J Immunol; 2006 Jan; 176(2):905-13. PubMed ID: 16393975
[TBL] [Abstract][Full Text] [Related]
11. MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo.
Krmpotić A; Busch DH; Bubić I; Gebhardt F; Hengel H; Hasan M; Scalzo AA; Koszinowski UH; Jonjić S
Nat Immunol; 2002 Jun; 3(6):529-35. PubMed ID: 12021778
[TBL] [Abstract][Full Text] [Related]
12. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
13. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60.
O'Callaghan CA; Cerwenka A; Willcox BE; Lanier LL; Bjorkman PJ
Immunity; 2001 Aug; 15(2):201-11. PubMed ID: 11520456
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142.
Chalupny NJ; Rein-Weston A; Dosch S; Cosman D
Biochem Biophys Res Commun; 2006 Jul; 346(1):175-81. PubMed ID: 16750166
[TBL] [Abstract][Full Text] [Related]
15. Expression of NKG2D and its ligand in mouse heart allografts may have a role in acute rejection.
Feng L; Ke N; Ye Z; Guo Y; Li S; Li Q; Li Y
Transplant Proc; 2009 Dec; 41(10):4332-9. PubMed ID: 20005394
[TBL] [Abstract][Full Text] [Related]
16. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity.
Andoniou CE; van Dommelen SL; Voigt V; Andrews DM; Brizard G; Asselin-Paturel C; Delale T; Stacey KJ; Trinchieri G; Degli-Esposti MA
Nat Immunol; 2005 Oct; 6(10):1011-9. PubMed ID: 16142239
[TBL] [Abstract][Full Text] [Related]
17. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
18. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
19. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
